|[September 26, 2013]
Diaxonhit Strengthens Its Offering in the Field of Quality Control for Clinical Laboratories
PARIS --(Business Wire)--
Regulatory News :
Diaxonhit (Paris:ALEHT) strengthens its offering in the field of quality
control for clinical laboratories with the signing by InGen, its
commercialization affiliate, of an exclusive agreement for France with
CODASY, the Belgian specialist of software solutions for private and
public clinical laboratories.
A growing demand for quality
With discussions continuing in the French Parliament, ongoing medical
biology reform already requires all laboratories to operate under new
regulatory requirements in terms of quality of performed tests. In
particular, clinical laboratories must obtain ISO 15189 accreditation to
operate with all qualifications required by the new quality standards.
Achieving and maintaining this certification require the daily use of
independent quality controls to validate the results of laboratory tests
performed in about 2 000 French clinical laboratories. Implementation of
these controls is complex, and laboratories do not necessarily have the
relevant expertise and means. Many institutions are looking for
solutions that simplify implementation and management of quality
controls, while limiting the number of required resources.
An integrated offering that meets the current needs of clinical
Diaxonhit already offers a range of quality control tests and reagents
to clinical laboratories in France by marketing partner products in the
field of viral and bacterial infections, Immunoassay, toxicology and
With this new exclusive partnership with CODASY for the implementation
of the QC Connect software, Diaxonhit now has an integrated offering for
implementation and management of quality, which targets specifically
clinical laboratories. QC Connect enables the integrated daily tracking
of quality checks performed on analyzers to measure deviations from
expected standards, to alert operators in case of failure and to provide
regulatory documentation related to controls and monitoring. With the
integration of the new software to its range of quality control tests,
Diaxonhit enables laboratories to more easily meet the requirements of
their ISO-15189 qualification while providing one-stop shopping for
A growing business
Diaxonhit sales in the field of quality control, which represented 4% of
its total product sales, increased by more than 14% in 2012. The first
half of 2013 confirms this trend with an increase of 17% compared to the
first half of 2012. With this new integrated offering Diaxonhit provides
a better response to the needs of its customers, and intends to
accelerate its penetration in this very promising market.
Diaxonhit (NYSE Alternext, FR0004054427, ALEHT) is a French fully
integrated leader in the in-vitro diagnostic field, involved from
research to commercialization of specialty diagnostic products.
With many partnerships and a strong presence in hospitals, Diaxonhit has
an extensive commercialization network. Through its affiliate, InGen, it
commercializes and services, mostly under exclusivity agreements,
in-vitro diagnostic kits and advanced equipment. It operates mainly in
the fields of transplantation, infectious diseases and autoimmunity,
product quality control and rapid tests, including Tetanus Quick Stick
®, a proprietary product. InGen is the leading supplier in France of HLA
tests manufactured by Thermo-Fisher/One Lambda, of which it is the
largest distributor worldwide.
The group also owns a diversified portfolio of products in development,
including both innovative molecular and non-molecular diagnostics,
covering three main specialty areas: immuno-infection, Alzheimer's
disease and cancer.
Diaxonhit headquarters are located in Paris and its affiliate in the
Paris region. The Group is listed on NYSE Alternext in Paris and is part
of the NYSE Alternext OSEO innovation index.
For more information, please visit: http://www.diaxonhit.com.
This press release contains elements that are not historical facts
including, without limitation, certain statements about future
expectations and other forward-looking statements. Such statements are
based on management's current views and assumptions and involve known
and unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those anticipated.
In addition, Diaxonhit, its shareholders, and its affiliates,
directors, officers, advisors and employees have not verified the
accuracy of, and make no representations or warranties in relation to,
statistical data or predictions contained in this press release that
were taken or derived from third party sources or industry publications,
and such statistical data and predictions are used in this press release
for information purposes only.
Finally, this press release may be drafted in the French and English
languages. In an event of differences between the texts, the French
language version shall prevail.
[ Back To Technology News's Homepage ]